A judge’s decision in February to vacate the federal government’s letter telling AstraZeneca its 340B contract pharmacy policy is illegal was our top breaking news story of 2022.
Number two on the list (based on how often a story page was loaded) was our scoop in September that the U.S. Department of Health and Human Services Office of Inspector General had no plans at that time to impose civil monetary penalties on drug manufacturers restricting 340B pricing in the contract pharmacy setting.
A judge’s decision in February to vacate the federal government’s letter telling AstraZeneca its 340B contract pharmacy policy is illegal was our top breaking news story of 2022.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
